Guizhou Xinbang Pharmaceutical Co Ltd
SZSE:002390
Guizhou Xinbang Pharmaceutical Co Ltd
Net Income (Common)
Guizhou Xinbang Pharmaceutical Co Ltd
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Guizhou Xinbang Pharmaceutical Co Ltd
SZSE:002390
|
Net Income (Common)
¥230m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
19%
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Net Income (Common)
¥3.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Net Income (Common)
¥2.8B
|
CAGR 3-Years
21%
|
CAGR 5-Years
22%
|
CAGR 10-Years
21%
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Net Income (Common)
¥4.2B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
2%
|
CAGR 10-Years
13%
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Net Income (Common)
¥4.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
6%
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Net Income (Common)
¥755.6m
|
CAGR 3-Years
36%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
See Also
What is Guizhou Xinbang Pharmaceutical Co Ltd's Net Income (Common)?
Net Income (Common)
230m
CNY
Based on the financial report for Sep 30, 2023, Guizhou Xinbang Pharmaceutical Co Ltd's Net Income (Common) amounts to 230m CNY.
What is Guizhou Xinbang Pharmaceutical Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
19%
Over the last year, the Net Income (Common) growth was -24%. The average annual Net Income (Common) growth rates for Guizhou Xinbang Pharmaceutical Co Ltd have been 13% over the past three years , -7% over the past five years , and 19% over the past ten years .